My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about QSTG

    LOS ANGELES, May 18 /PRNewswire-FirstCall/ -- Quest Group
 International, Inc. ("Quest") (OTC Bulletin Board:   QSTG) today announced
 that it entered into a license agreement with Vitae Pharmaceuticals, Inc.,
 a privately held company, ("Vitae"), under which it acquired an extensive
 portfolio of technology and intellectual property around nuclear receptors
 with new generation oncology product candidates for blood and solid tumor
 cancers and cancer supportive care. Quest also announced the completion of
 a $20 million private placement and detailed its product development
 pipeline.
     The extensive portfolio of compounds acquired from Vitae includes
 selective retinoic acid receptor agonists and antagonists and rexinoids,
 the latter being small molecule synthetic compounds. Quest plans to
 implement research and development of three lead compounds. Each compound
 represents a unique chemical structure, unique class of therapy, and unique
 pharmacological function. The first compound will enter phase 2 study for
 the treatment of acute leukemia; the second lead compound will be tested
 for safety in humans followed by efficacy studies in some of the most
 common cancers, including lung and breast cancer. A novel third program is
 intended to evaluate and develop a lead compound as therapy to reduce the
 toxicity of chemotherapy, in particular, diminish the risk of infection as
 consequence of reduction in white blood cell count. In addition to these
 three lead compounds Quest has acquired a platform of technology,
 intellectual property, and a large library of small molecules, that will be
 used for additional discoveries of novel therapeutics.
     Dr. Parkash Gill, who will serve as Quest's Chairman of the Scientific
 Board, said, "Quest now represents the single largest concentration of
 retinoid/rexinoid therapeutics in the world. The company hopes to deliver
 on the promise of these therapeutics to drive tumor cells towards
 differentiation and/cell death. This approach may also incorporate rational
 combination with other therapeutics."
     Dr. Harin Padma-Nathan, who will serve as Quest's Chief Executive
 Officer, said, "We are pleased to announce the acquisition of an extensive
 portfolio of technology and intellectual property around nuclear receptors
 with new generation product candidates in clinical testing for both blood
 and solid tumor cancers and cancer supportive care. Our experience and
 expertise in R&D and drug development in oncology coupled with our long
 standing working relationships with the leading cancer centers in the world
 brings us added confidence to rapidly advance this novel nuclear receptor
 platform. In addition, we have secured strong financial backing from
 institutions that will allow us drive our product development pipeline."
     $20 Million Private Placement
     Quest Group International, Inc. raised $20 million in gross proceeds
 from institutional investors in a private placement of common stock. Hunter
 World Markets, Inc. of Beverly Hills, California acted as the Company's
 sole placement agent. Todd Ficeto, President and Chief Executive Officer of
 Hunter World Markets, Inc., said, "I am very pleased to be a part of this
 venture and help provide the resources that enable this group of
 distinguished scientist with extensive experience in developing some of the
 biggest pharmaceutical products of the past decade including Viagra and
 Taxol, to acquire and develop exciting new generation oncology products."
     Management
     Dr. Harin Padma-Nathan will serve as Quest's Chief Executive Officer.
 He brings over 20 years of experience in clinical research, drug
 development, and regulatory experience. He has been a Professor of Clinical
 Urology at the Keck School of Medicine of the University of Southern
 California, Medical Director of The Male Clinic, and Chief Scientific
 Officer at Insyght Interactive. Dr. Padma-Nathan has also been involved in
 numerous clinical research studies and served as the principal investigator
 for Viagra and was a lead investigator for other therapies in the field of
 erectile dysfunction. Additionally, his clinical research experience
 extends to hypertension, BPH, incontinence, coronary artery disease, female
 sexual dysfunction, and prostate cancer. He is extensively published,
 including in the New England Journal of Medicine.
     Dr. Parkash Gill will serve as Quest's Chairman of the Scientific
 Board. He is an internationally recognized authority in cancer and vascular
 biology, identification and development of therapeutics with application in
 cancer, diabetic retinopathy, and macular degeneration. He has played a
 pivotal role in the development of three marketed drugs including Taxol(R)
 Paxene(R) and DaunoXome(R) and has served on FDA Advisory Committees. He
 has been a Professor of Medicine (Hematology, Oncology and Pathology) at
 the Keck School of Medicine of the University of Southern California since
 July 1999. He has held an endowed chair in Cancer Therapeutic at the same
 institution since July 2005. He has authored nearly 200 research
 publications in oncology. Dr. Gill has also demonstrated entrepreneur
 translation of his research into viable companies, most recently, Vasgene
 Therapeutics.
     About Hunter World Markets, Inc. (HWM)
     Based in Beverly Hills, California, Hunter World Markets, Inc. (HWM) is
 a member of NASD and SIPC and offers investment banking, investment
 advisory and institutional trading to select clients with a diversity of
 sector and industry experience, particularly in North American and European
 markets. HWM has equity underwriting capabilities that include capital
 rising through initial public offerings and private placements. In
 institutional trading, HWM offers highly individualized trading services to
 investment advisors, asset managers, pension funds, insurance companies,
 hedge funds, banks and other institutional investors, and trades on all
 major exchanges in North America and Europe through RBC Dain Rauscher Inc.
     About Vitae Pharmaceuticals, Inc.
     Vitae Pharmaceuticals is an emerging pharmaceutical company dedicated
 to being a leader in rapidly discovering, developing and commercializing
 innovative, high value, small molecule medicines, focusing on known
 biologic targets with significant unmet medical need. Vitae's two lead
 programs are rapidly advancing in the cardiovascular and diabetes
 therapeutic areas. Vitae's first and lead program is in renin inhibition
 for the treatment of hypertension. Vitae and GlaxoSmithKline formed one of
 2005's largest preclinical partnerships to continue to advance Vitae's
 renin program.
     About Quest Group International, Inc.
     Quest Group is an emerging pharmaceutical company with a focus on
 nuclear receptor target therapeutics. Quest is pleased to announce the
 acquisition of an extensive portfolio of technology and intellectual
 property around nuclear receptors with new generation product candidates in
 clinical testing for both blood and solid tumor cancers and cancer
 supportive care. This extensive portfolio of compounds includes selective
 retinoic acid receptor agonists and antagonists and rexinoids, the latter
 being small molecule synthetic compounds. Quest plans to implement research
 and development of three lead compounds. Each compound represents a unique
 chemical structure, unique class of therapy, and unique pharmacological
 function. The first compound will enter phase 2 study for the treatment of
 acute leukemia, the second lead compound will be tested for safety in
 humans followed by efficacy studies in some of the most common cancers,
 including lung and breast cancer. A novel third program is intended to
 evaluate and develop a lead compound as therapy to reduce the toxicity of
 chemotherapy, in particular, to diminish the risk of infection as
 consequence of reduction in white blood cell count. In addition to these
 three lead compounds, Quest has acquired a platform of technology,
 intellectual property, and a large library of small molecules, which will
 be used for additional discoveries of novel therapeutics. A group of highly
 talented and experienced scientists in this field will lead the Quest
 research efforts. The Company has the necessary skills and chemical
 resources to produce novel therapies for other human diseases such as bone
 repair and healing, cartilage loss, lipid metabolic defects, and diabetes
 mellitus.
     The Company, from time to time, may discuss forward-looking
 information. Except for the historical information contained in this
 release, all forward- looking statements are predictions by the Company's
 management and are subject to various risks and uncertainties that may
 cause results to differ from management's current expectations. Such
 factors include the fact that the Company is engaged in early stage
 research and does not expect to obtain any revenues for several years and
 other risks as detailed from time to time in the Company's registration
 statement and reports and filings with the Securities and Exchange
 Commission. All forward-looking statements, if any, in this release
 represent the Company's judgment as of the date of this release. The
 Company disclaims, however, any intent or obligation to update
 forward-looking statements.
 
 

SOURCE Quest Group International, Inc.